Authors
Latest:
Ecolab Continues Mission to Protect What's Vital With Deep Investment in Life SciencesEcolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.
Latest:
PREP Act Protections for COVID-19 Vaccine LiabilityHow PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Latest:
Best Practices for Balancing Medical Affairs Globalization with Local RequirementsAddressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Latest:
The IRA Impact: Navigating Its Evolving ComplexitiesAmid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Latest:
China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global InvestmentA look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Latest:
The Quest to Fully Address Prescription Drug AffordabilityThe Medicare Part D cap won’t solve need for financial assistance.
Latest:
The JAKs Journey Offers Valuable Lessons for InnovatorsOpportunity remains despite regulatory and access obstacles.
Latest:
Why A New Mix of Field Skills is Crucial to Thriving in the Digital EraEvolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.
Latest:
SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan DiseasesThe introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
Latest:
The Department of Justice is Watching: Building a Data-Driven Compliance ProgramWhether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.
Latest:
When to Utilize Commercial OutsourcingWhen deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian MomentThe recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
Navigating the Payer-Health System Nexus: A Strategic Imperative for Biopharma Commercial SuccessThe traditional biopharma approach focused primarily on physician detailing and securing favorable payer contracts, has become inadequate in today’s market.
Latest:
China: The Giant Has AwokenWith a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
Latest:
The Consolidated Appropriations Act and PBM TransparencyNew federal law introduces significant changes in the design of pharmacy benefit plans with aims to level the playing field between PBMs and their employee healthcare benefit plan clients.
Latest:
Embracing the Hybrid Era: Leveraging Answer Engines and Generative AI to Improve the Patient and HCP ExperienceThrough the power of large language models and generative AI, pharma and biotech companies are transforming medical information delivery by offering direct, trustworthy, and accurate answers to patients and healthcare providers, significantly reducing time and frustration.
Latest:
Enhancing Supply Chain Resilience amid Complexity in Pharma and Medical DevicesThe growing complexity of supply chains necessitates the adoption of collaborative planning processes and capabilities such as S&OP and S&OE.
Latest:
The Cultural Deficit in the Pharma Industry in the Era of COVID-19Multicultural campaigns crafted for diverse populations are insufficiently funded and do not receive the same support as mainstream campaigns, writes Sheila Thorne. While there are plenty of people willing to partner with pharma on these campaigns, will the industry wake up to the changing world ahead?
Latest:
Measuring Pharma’s Trust PerformanceThe core building blocks of trust must be operationalized for pharma companies to strengthen their social contract, deliver business value, and improve patients’ quality of life.
Latest:
Advancing Healthcare Solutions: Harnessing Collaborative Business Models for OncologyUnique approaches are needed to bring solutions to fighting cancer and bacterial-resistant infections.
Latest:
Don’t Get Distracted By AI, Instead Focus on Intellectual PropertyArtificial intelligence is making it quicker to get drug candidates to the clinic, but it isn’t addressing the fundamental need to marry the right candidate and the right target to the right disease.
Latest:
How Life Sciences Can Move to Manufacturing 4.0 While Meeting Market DemandsHere are four ways life sciences organizations can quickly and cost-effectively achieve Manufacturing 4.0 benefits while still getting treatments to market.
